TEDCO recently launched ‘TEDCO Talks’, a series featuring thought leaders in economic development across the State of Maryland. On May 28th, TEDCO CEO & Executive Director, Troy LeMaile-Stovall interviewed Sally Allain, Head of JLABS @ Washington DC, about the future of the innovation ecosystem and the crucial role that JLABS will play in advancing the BioHealth Capital Region.
With a visit from Maryland Governor Larry Hogan at the location of their future Vaccines Innovation Campus and Global Headquarters In Gaithersburg, positive data on their COVID-19 Variant Strain Vaccine, and a Phase 3 Trial showing 90% Overall Efficacy/100% Protection Against Moderate and Severe Disease in PREVENT-19. Novavax had one of the most newsworthy weeks to kick off the Summer of 2021.
Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious
diseases. As COVID-19 spread, dozens of Maryland companies joined the global response.
Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
AGT’s new COVID-19 testing capability provides less expensive, more convenient, and highly accurate same-day COVID-19 to its own staff and the general public. RT-PCR testing is the “Gold Standard” of COVID-19 tests; AGT’s testing program was designed to help its employees and other local organizations’ staff return to and remain safe in the workplace.
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, [….]
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]
Covid 19 Timeline Year 2020 *click article titles below to read original BioBuzz content from the past year MARCH 4/7/2020 Coronavirus Pandemic Good News Roundup Sheds Light Amidst Trying COVID-19 [….]
